Brief: Lee's Pharmaceutical Holdings Says NDA Of Teglutik Accepted For Review By NMPA
06/02/2020 12:03
Feb 6 (Reuters) - Lee's Pharmaceutical Holdings Ltd
0950.HK :
* NEW DRUG APPLICATION OF TEGLUTIK FOR TREATMENT OF
AMYOTROPHIC
LATERAL SCLEROSIS ACCEPTED FOR REVIEW BY NMPA
Source text for Eikon: ID:nHKS2TLlNJ
Further company coverage: 0950.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lees Pharmaceutical Holdings
See all newsBrief: Lee's Pharmaceutical Announces Share Repurchase Program Under Repurchase Mandate
Brief: Lee's Pharmaceutical To Receive Funding From Gates Foundation For Synthetic Surfactant Project
Brief: Lee's Pharmaceutical Says Zhaoke Hefei To Contribute Rmb25 Million To Partnership Fund
Brief: Lee's Pharmaceutical Declares Final Dividend Of HK2.3 Cents Per Share
Brief: Lee's Pharmaceutical Reports Approval Of Intrarosa By NMPA